Last reviewed · How we verify

NCT06930235

Effectiveness of Midodrine as an Adjuvant to Norepinephrine in Weaning Critically Ill Patients From Vasopressors

Recruiting now NA Last updated 16 April 2025
What this trial tests

NA trial testing Weaning critically ill patients from norepinephrine using midodrine as an adjuvant to norepinephrine in Shock in 112 participants. Currently enrolling.

Timeline
13 March 2025
Primary endpoint
13 October 2025
13 October 2025

Quick facts

Lead sponsorSohag University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment112
Start date13 March 2025
Primary completion13 October 2025
Estimated completion13 October 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Sohag University

Who can join

18 and older, any sex, with Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the effectiveness of midodrine as an adjuvant to norepinephrine in weaning critically ill patients from vasopressors

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Shock

Currently open trials in the same condition.

Other Sohag University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06930235.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing